eClinical Technology News

Thursday, February 21, 2008 10:04 AM
  • Cleveland, Ohio-based Datatrak inked an enterprise agreement for at least $800,000, depending on the extent of services required by the client. The agreement is a three-year subscription license with an unnamed pharmaceutical company in Europe. The model is a contracting mechanism for the company’s platform is a separate option to its “trial by trial” model. Datatrak stated its typical “revenue composition” has been 25% for the technology element of an eClinical implementation and 75% for services. “We believe that we will always have the trial-by-trial business model, because this is more appropriate for clients with smaller pipelines. However, for clients with more predictable and larger pipelines, this model provides very predictable research and development costs and eliminates wasted time involved with negotiation and contracting under the trial-by-trial mode,” stated Jeffery Green, Pharm.D., chief executive officer of Datatrak.
  • Seattle, Wash.-based Advanced Clinical Software (ACS) has launched a new version of its clinical trial management software (CTMS) product StudyManager, called StudyManager Sponsor Edition. The product is gear towards smaller sponsors, which may not have internal CTMS platforms. The new edition provides data collection, study management and real-time site/monitor interaction. “I root for the underdog,” said Bruce Schatzman, ACS’s founder and chief executive officer. “Most middle-tier research sponsors we’re addressing with our new product have been dwarfed for years by Big Pharma, which has the resources to purchase high-priced CTMS and electronic data capture (EDC) programs,” he said.
  • Research Triangle Park, N.C.-based contract research organization (CRO) StatWorks has selected Akaza Research’s Open Clinica Enterprise for its EDC needs. Open Clinica is an open source, web-based, EDC software system that can be integrated into any existing infrastructure with internal client coding.
  • India-based CRO SIRO Clinpharm (SIRO) is implementing a new IT framework using Oracle’s Life Sciences Applications and will use Sun Microsystems’ (Sun) hardware platform. This IT infrastructure will be implemented by DBMS Consulting, an Oracle partner network company.
  • Waltham, Mass.-based Phase Forward will be moving to a 165,000 square-foot headquarters housed in a new state-of-the-art, green certified business center. The office is approximately five miles from the eClinical company’s current headquarters at 880 Winter St. The building has been certified by the U.S. Green Building Council (USGBC). A “Green” certification requires specific standards to be met in sustainability, water efficiency, energy, materials and resource, and indoor environmental quality. Phase Forward stated its accelerated growth, and anticipated new growth, created the need for a much larger office space. “Our high-caliber workforce has been key to our strong growth, so remaining in the Waltham area was a critical factor in recruiting and retaining employees and minimizing commute times,” said Bob Weiler, president and chief executive officer of Phase Forward.
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs